UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 (State or other jurisdiction of incorporation or organization) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. (Address of Principal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2020 or For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada V6C 1B4 (A ...

InMed Pharmaceuticals Inc. (IMLFF) Q4 2020 Earnings Conference Call September 8, 2020 11:30 AM ET Company Participants Brendan Payne - Director, Investor Relations Eric Adams - President & Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Pre-Clinical Research & Development Alexandra Mancini - Senior Vice President, Clinical & Regulatory Affairs Conference Call Participants Maxim Jacobs - Edison Group Operator Good morning. My name is Veronica, and IÂ'll be yo ...

U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Corporate Presentation September 2020 www.inmedpharma.com :IN :IMLFF Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company's continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this prese ...

InMed Pharmaceuticals Inc. (IMLFF) Q3 2020 Earnings Conference Call May 14, 2020 11:30 AM ET Company Participants Brendan Payne – Director-Investor Relations Eric Adams – President and Chief Executive Officer Bruce Colwill – Chief Financial Officer Alexandra Mancini – Senior Vice President-Clinical and Regulatory Affairs Eric Hsu – Senior Vice President-Preclinical Research and Development Conference Call Participants Scott Henry – ROTH Capital Jim Molloy – Alliance Global Max Jacobs – Edison Group Operator ...

U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Investor Presentation May 2020 www.inmedpharma.com :IN :IMLFF 2 Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company's continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this presentati ...

U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Investor Presentation February 2020 www.inmedpharma.com :IN :IMLFF 2 Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company's continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this prese ...

Financial Data and Key Metrics Changes - Research and development (R&D) spending increased to approximately CAD1.9 million for Q2 2020, compared to CAD1 million for the same period in 2019, and totaled approximately CAD4.3 million for the six months ended December 31, 2019, up from CAD1.6 million in the prior year [23][24] - General and administrative (G&A) expenses were approximately CAD1 million for Q2 2020, slightly higher than CAD900,000 for the same period in 2019, totaling CAD1.9 million for the six months ended December 31, 2019, compared to CAD1.7 million in the previous year [25] - The company recorded a net loss of CAD3.4 million for Q2 2020 and CAD6.7 million for the six months ended December 31, 2019, compared to a net loss of CAD2.7 million and CAD5.5 million for the same periods in 2018 [29][30] - Cash reserves decreased to CAD12 million as of December 31, 2019, down from CAD14.8 million at the end of the previous quarter and CAD18 million at the end of June 30, 2019 [31] Business Line Data and Key Metrics Changes - The company initiated its first human clinical trial for INM-755 for Epidermolysis Bullosa, becoming the first to advance a pharmacological formulation of cannabinol (CBN) in clinical trials [12][16] - INM-088 is being targeted for glaucoma treatment, with encouraging preclinical results suggesting potential therapeutic effects [17] Market Data and Key Metrics Changes - The company reported significant interest from clinicians and patients at the EB 2020 World Congress, indicating a strong market response to its development program for INM-755 [36][40] - The company is exploring various funding sources, including grants, to support its capital needs, particularly for its biosynthesis program [81] Company Strategy and Development Direction - The company aims to establish itself as a leader in innovative biosynthesis-based production of cannabinoids, focusing on competitive cost and GMP-grade production for pharmaceutical applications [19] - The company is committed to advancing its therapeutic programs and biosynthesis process development while exploring options for securing necessary capital [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in securing capital to continue advancing therapeutic programs and biosynthesis development, highlighting operational flexibility to manage R&D expenditures [33] - The company anticipates a tremendously exciting year with more milestones than ever before, indicating a positive outlook for future developments [86] Other Important Information - The company has filed amended financials due to a restatement of non-cash share-based payments, which did not affect cash reserves or operational cash use [27][28] - The company is actively pursuing options to meet its medium- to long-term capital needs while maintaining operational flexibility [34] Q&A Session Summary Question: What sort of response do you get from clinicians and patients at the EB Congress? - The response was excellent, with significant interest in the topical cream and the cannabinoid-based product, highlighting the comprehensive program and good results from preclinical studies [36][40] Question: Will data from the two different studies for INM-755 be released at the same time? - Results will be released at different times, with the intact skin study results coming out first [41] Question: Are the prospective pathways for cannabinoid production separate from the original and alternative processes? - The focus remains on the two processes, with ongoing data generation to compare specific parameters for decision-making [46][49] Question: How does CBN compare to THC for glaucoma treatment? - CBN outperformed THC in neuroprotection and stability, making it a favorable candidate for treatment [72][73] Question: What is the regulatory status of CBN in the U.S.? - CBN will start as a scheduled product due to its classification as a cannabinoid, but it may change over time with demonstrated safety and efficacy [75] Question: Is there a chance of securing additional grant funding? - The company has successfully secured non-dilutive funding in the past and will continue to pursue grant opportunities on a project-by-project basis [81]

Company Overview - InMed is focused on developing cannabinoid pharmaceuticals for diseases with high unmet medical needs, researching rare cannabinoids beyond THC & CBD [11] - The company is developing a biosynthetic manufacturing approach to achieve low-cost production of biologically identical cannabinoids [11] - The company's cash equivalents and short-term investments were C$14.8 million (US$11.2 million) as of September 30, 2019 [36] INM-755 for Epidermolysis Bullosa (EB) - INM-755 is being investigated for symptomatic relief in all EB patients, potentially accelerating wound healing, reducing pain and itch, and reducing inflammation [21] - Clinical trials for INM-755 include Phase I studies in healthy volunteers and Phase I/II studies in EB patients [23] - The company initiated a Phase 1 trial (755-101-HV) [24] INM-088 for Glaucoma - INM-088 targets reducing intraocular pressure (IOP) and providing neuroprotection for retinal ganglion cells (RGCs) in glaucoma [27] - The company plans to complete formulation development and proof-of-concept animal studies in the first half of 2020 [28] Manufacturing and Intellectual Property - The company is developing a proprietary biosynthesis process for cannabinoid manufacturing, offering cost savings and enhanced purity compared to extraction from plants or chemical synthesis [13, 16] - The company has a patent portfolio including methods for treating EBS with cannabinoids (INM-755) and cannabinoid-based therapy for glaucoma (INM-088) [31] - The company has 172.3 million shares outstanding [36]